191 related articles for article (PubMed ID: 37778781)
1. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.
Asselah T
Clin Liver Dis; 2023 Nov; 27(4):985-995. PubMed ID: 37778781
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hepatitis D: an unmet medical need.
Caviglia GP; Rizzetto M
Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
[TBL] [Abstract][Full Text] [Related]
3. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
Nkongolo S; Hollnberger J; Urban S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments.
Shekhtman L; Duehren S; Etzion O; Cotler SJ; Dahari H
Curr Gastroenterol Rep; 2023 Dec; 25(12):401-412. PubMed ID: 37819559
[TBL] [Abstract][Full Text] [Related]
5. HBV/HDV Coinfection: A Challenge for Therapeutics.
Koh C; Da BL; Glenn JS
Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
7. Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.
Asselah T
J Viral Hepat; 2023 Apr; 30 Suppl 1():33-38. PubMed ID: 36529713
[TBL] [Abstract][Full Text] [Related]
8. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
Soriano V; Moreno-Torres V; Treviño A; Corral O; de Mendoza C
Drug Des Devel Ther; 2023; 17():155-166. PubMed ID: 36712949
[TBL] [Abstract][Full Text] [Related]
9. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection.
Sandmann L; Wedemeyer H
Clin Liver Dis; 2021 Nov; 25(4):831-839. PubMed ID: 34593156
[TBL] [Abstract][Full Text] [Related]
10. Bulevirtide and emerging drugs for the treatment of hepatitis D.
Xu HY; Yang JO; Chen PH; Han SB
Expert Opin Biol Ther; 2023; 23(12):1245-1253. PubMed ID: 37853604
[TBL] [Abstract][Full Text] [Related]
11. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
[TBL] [Abstract][Full Text] [Related]
13. Emerging concepts for the treatment of hepatitis delta.
Elazar M; Glenn JS
Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
[TBL] [Abstract][Full Text] [Related]
14. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
[TBL] [Abstract][Full Text] [Related]
15. New therapies for hepatitis delta virus infection.
Loureiro D; Castelnau C; Tout I; Boyer N; Narguet S; Menasria Benazzouz S; Louis Z; Pons-Kerjean N; Giuly N; Marcellin P; Mansouri A; Asselah T
Liver Int; 2021 Jun; 41 Suppl 1():30-37. PubMed ID: 34155804
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
Sandmann L; Deterding K; Bremer B; Port K; Cornberg M; Wedemeyer H; Maasoumy B
J Viral Hepat; 2023 Apr; 30(4):283-286. PubMed ID: 36648369
[TBL] [Abstract][Full Text] [Related]
17. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis D virus: Improving virological knowledge to develop new treatments.
Khalfi P; Kennedy PT; Majzoub K; Asselah T
Antiviral Res; 2023 Jan; 209():105461. PubMed ID: 36396025
[TBL] [Abstract][Full Text] [Related]
19. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Deterding K; Wedemeyer H
AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
[TBL] [Abstract][Full Text] [Related]
20. [Chronic hepatitis B and D (delta) : Current and future treatments].
Wortmann N; Höner Zu Siederdissen C; Cornberg M
Internist (Berl); 2018 Jun; 59(6):519-527. PubMed ID: 29761292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
